TY - JOUR
T1 - Exploring the Role of Target Expression in Treatment Efficacy of Antibody–Drug Conjugates (ADCs) in Solid Cancers
T2 - A Comprehensive Review
AU - Mathiot, Laurent
AU - Baldini, Capucine
AU - Letissier, Octave
AU - Hollebecque, Antoine
AU - Bahleda, Rastislav
AU - Gazzah, Anas
AU - Smolenschi, Cristina
AU - Sakkal, Madona
AU - Danlos, François Xavier
AU - Henon, Clémence
AU - Beshiri, Kristi
AU - Goldschmidt, Vincent
AU - Parisi, Claudia
AU - Patrikidou, Anna
AU - Michot, Jean Marie
AU - Marabelle, Aurélien
AU - Postel-Vinay, Sophie
AU - Bernard-Tessier, Alice
AU - Loriot, Yohann
AU - Ponce, Santiago
AU - Champiat, Stéphane
AU - Ouali, Kaïssa
N1 - Publisher Copyright:
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024.
PY - 2024/1/1
Y1 - 2024/1/1
N2 - Purpose of Review: Antibody–drug conjugates (ADCs) offer a promising path for cancer therapy, leveraging the specificity of monoclonal antibodies and the cytotoxicity of linked drugs. The success of ADCs hinges on precise targeting of cancer cells based on protein expression levels. This review explores the relationship between target protein expression and ADC efficacy in solid tumours, focusing on results of clinical trials conducted between January 2019 and May 2023. Recent Findings: We hereby highlight approved ADCs, revealing their effectiveness even in low-expressing target populations. Assessing target expression poses challenges, owing to variations in scoring systems and biopsy types. Emerging methods, like digital image analysis, aim to standardize assessment. The complexity of ADC pharmacokinetics, tumour dynamics, and off-target effects emphasises the need for a balanced approach. Summary: This review underscores the importance of understanding target protein dynamics and promoting standardized evaluation methods in shaping the future of ADC-based cancer therapies.
AB - Purpose of Review: Antibody–drug conjugates (ADCs) offer a promising path for cancer therapy, leveraging the specificity of monoclonal antibodies and the cytotoxicity of linked drugs. The success of ADCs hinges on precise targeting of cancer cells based on protein expression levels. This review explores the relationship between target protein expression and ADC efficacy in solid tumours, focusing on results of clinical trials conducted between January 2019 and May 2023. Recent Findings: We hereby highlight approved ADCs, revealing their effectiveness even in low-expressing target populations. Assessing target expression poses challenges, owing to variations in scoring systems and biopsy types. Emerging methods, like digital image analysis, aim to standardize assessment. The complexity of ADC pharmacokinetics, tumour dynamics, and off-target effects emphasises the need for a balanced approach. Summary: This review underscores the importance of understanding target protein dynamics and promoting standardized evaluation methods in shaping the future of ADC-based cancer therapies.
KW - Antibody–drug conjugate
KW - Immunohistochemistry
KW - Objective response rate
KW - Target expression
UR - http://www.scopus.com/inward/record.url?scp=85200025106&partnerID=8YFLogxK
U2 - 10.1007/s11912-024-01576-9
DO - 10.1007/s11912-024-01576-9
M3 - Review article
C2 - 39066847
AN - SCOPUS:85200025106
SN - 1523-3790
JO - Current Oncology Reports
JF - Current Oncology Reports
ER -